Pancreastatin inhibitor activates AMPK pathway via GRP78 and ameliorates dexamethasone induced fatty liver disease in C57BL/6 mice
-
Add time:08/25/2019 Source:sciencedirect.com
AimsTo investigate the role of pancreastatin inhibitor (PSTi8) in lipid homeostasis and insulin sensitivity in dexamethasone induced fatty liver disease associated type 2 diabetes.
We also recommend Trading Suppliers and Manufacturers of pancreastatin-29 (cas 113817-19-9). Pls Click Website Link as below: cas 113817-19-9 suppliers
Prev:Original articleThe occurrence of pancreastatin in tumours of the diffuse neuroendocrine system
Next:Southern surgical association articleElevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Pancreastatin, a Regulatory Peptide Derived From Chromogranin A☆08/27/2019
- Southern surgical association articleElevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum08/26/2019
- Original articleThe occurrence of pancreastatin in tumours of the diffuse neuroendocrine system08/24/2019
- ArticleChromogranin A(210–301) is the major form of pancreastatin-like material in human gut extracts and endocrine tumors08/23/2019
- ArticleEffects of synthetic human pancreastatin on pancreatic secretion and blood flow in rats and dogs08/22/2019
